Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Silexion Therapeutics Corp

Get SEC filing alerts via email and in your feed for Silexion Therapeutics Corp

SLXN SLXNW

Silexion Therapeutics Corp

About Silexion Therapeutics Corp

Silexion Therapeutics is a clinical-stage biotech specializing in RNA interference therapies targeting KRAS-driven cancers, notably pancreatic cancer. Its lead candidate, SIL204, aims to silence mutant KRAS genes using intratumoral delivery, with a focus on locally advanced pancreatic tumors. The company develops personalized, targeted treatments to improve survival outcomes, leveraging proprietary technology and strategic collaborations in oncology markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Silexion Therapeutics Corp

1
1
Silexion Therapeutics Corp Silexion Therapeutics Reports $2.7 Million Net Loss in Q1 2026

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Silexion Therapeutics Corp Silexion Therapeutics Reports Annual Financial Results and Focus on KRAS-Driven Cancer Treatments

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Silexion Therapeutics Corp Silexion Therapeutics Reports $7.5 Million Net Loss for Nine-Month Period Ending September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Silexion Therapeutics Corp Silexion Therapeutics Reports $4.2 Million Net Loss for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Silexion Therapeutics Corp Silexion Therapeutics Reports Q1 2025 Financial Results with Increased Net Loss and Improved Cash Position

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Silexion Therapeutics Corp Silexion Therapeutics Reports $16.5 Million Net Loss for 2024, Plans Phase 2/3 Trial for SIL204

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Silexion Therapeutics Corp Silexion Therapeutics Reports Significant Net Loss and Operating Expenses Increase in Nine Months Ended September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

8
1
Silexion Therapeutics Corp Silexion Therapeutics Reports Significant Financial Challenges and Doubt About Its Ability to Continue as a Going Concern

Via official filing (AI summary) | almost 2 years ago | 0 comments